Answers are grounded in this paper and cite their sources.
Background: In 2023, Washington State mandated that all antiretroviral drugs (ARVs) be made available to Medicaid-insured people with HIV (PWH) without prior authorizations, a change estimated to increase ARV spending by ∼20%. How this policy aligns with patient priorities is unknown. Setting: Seattle, Washington, USA Methods: We administered a best-worst scaling survey to 148 Medicaid-insured PWH to assess 9 options for allocating new HIV-related spending: 1) unrestricted access to all ARVs (unrestricted utilization) or restricted utilization of some ARVs plus each of the following 2) $200/month cash, 3) $200/month rental/utility assistance, 4) $200/month food assistance, 5) better dental care access, 6) better substance abuse treatment access, 7) better mental health care access, 8) better access to walk-in HIV care, or 9) additional case management. Participants separately rated choices as most and least helpful for themselves and for all PWH. We used conditional logistic regression to calculate preferences for each option. Results: Most participants were White (55%), male (80%), and had incomes <$1000/month (69%). When selecting options for themselves, participants’ 3 most preferred choices were restricted ARV utilization plus $200/month for cash, rent/utility assistance, or food; model findings suggest that 47% participants considered one of these options as their most preferred choice vs. 8% prioritizing unrestricted ARV utilization. Preferences for self and community were mostly aligned. Conclusion: This patient population prioritized economic support over accessing more costly ARVs or other services. Current HIV-related public spending prioritizing expensive ARVs over patients’ socioeconomic needs may not be aligned with patient preferences.
No takes yet. Share an insight, caveat, or question.
Golden et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: